Zubrin

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
08-05-2012
Summary of Product characteristics Summary of Product characteristics (SPC)
08-05-2012

Active ingredient:

тепоккалин

Available from:

Intervet International B. V.

ATC code:

QM01AE92

INN (International Name):

tepoxalin

Therapeutic group:

Кучета

Therapeutic area:

Мускулно-скелетна система

Therapeutic indications:

Намаляване на възпалението и облекчаване на болката, причинена от остри и хронични мускулно-скелетни нарушения.

Product summary:

Revision: 13

Authorization status:

Отменено

Authorization date:

2001-03-13

Patient Information leaflet

                                B. ЛИСТОВКА ЗА УПОТРЕБА
Лекарствен продукт, който вече не е
разрешен за употреба
ЛИСТОВКА ЗА УПОТРЕБА
Zubrin, перорална таблетка за кучета
1.
ИМЕ И ПОСТОЯННИЯ АДРЕС НА УПРАВЛЕНИЕ
НА ПРИТЕЖАТЕЛЯ НА
ЛИЦЕНЗА ЗА УПОТРЕБА И НА
ПРОИЗВОДИТЕЛЯ, АКО ТЕ СА РАЗЛИЧНИ
ЛИЦА
ПРИТЕЖАТЕЛ НА
ЛИЦЕНЗА ЗА УПОТРЕБА
:
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands
УПЪЛНОМОЩЕН ПРОИЗВОДИТЕЛ, ОТГОВОРЕН
ЗА ОСВОБОЖДАВАНЕ НА ПАРТИДАТА
:
S-P Veterinary Ltd
Breakspear Road South
Hаrefield
Uxbridge UB9 6LS
United Kingdom
2.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Zubrin 50 mg перорална таблетка за кучета
Zubrin 100 mg перорална таблетка за кучета
Zubrin 200 mg перорална таблетка за кучета
3.
СЪДЪРЖАНИЕ НА АКТИВНИТЕ СУБСТАНЦИИ И
ПОМОЩНИТЕ ВЕЩЕСТВА
Tepoxalin 50 mg перорална таблетка
Tepoxalin 100 mg перорална таблетка
Tepoxalin 200 mg перорална таблетка
4. ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
За ограничаване на на въз
палението и болката, причинени от
остри и хронични заболявания на
мускулатурата и костната система.
5. ПРОТИВОПОКАЗАНИЯ
Да не се използва при :
•
Бременни и лактиращи кучета и при
женските животни предназначени за
разплод
•
Животни със сърдечносъдови или
чернодробни заболявания
•
животни с язва на стомашно
                                
                                Read the complete document

Summary of Product characteristics

                                ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
Лекарствен продукт, който вече не е
разрешен за употреба
1.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Zubrin 50 mg перорална таблетка за кучета
Zubrin 100 mg перорална таблетка за кучета
Zubrin 200 mg перорална таблетка за кучета
2.
КОЛИЧЕСТВЕН И КАЧЕСТВЕН И СЪСТАВ
АКТИВНА СУБСТАНЦИЯ(И):
Tepoxalin 50 mg
Tepoxalin 100 mg
Tepoxalin 200 mg
За пълен списък на помощните вещества,
виж т. 6.1.
3.
ФАРМАЦЕВТИЧНА ФОРМА
Перорална таблетка
4.
КЛИНИЧНИ ДАННИ
4.1
ВИДЪТ ЖИВОТНИ, ЗА КО
ИТО Е ПРЕДНАЗНАЧЕН ВМП
Кучета
4.2
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ ЗА ОТДЕЛНИТЕ
ВИДОВЕ ЖИВОТНИ
За ограничаване на възпалението и
болката, причинени от остри и хронични
заболявания на
мускулатурата и костната система.
4.3
ПРОТИВОПОКАЗАНИЯ
Да не се използва при бременни или
лактиращи животни. Да не се използва
при животни за
разплод.
Употребата на проду
кта е противопоказана при животни,
страдащи от сърдечносъдови и
чернодробни заболявания или при
животни с установени стомашночревни
язви, кръвотечения
или с установена свръхчувствителност
към продукта.
Да не се използва при кучета с
дехидратация, хиповолемия или
хипотония, поради опасност от

                                
                                Read the complete document

Similar products

Active ingredient тепоккалин

тепоккалин

ATC code QM01AE92

QM01AE92

Marketed by Intervet International B. V.

Intervet International B. V.

INN (International Name) tepoxalin

tepoxalin

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 08-05-2012
Summary of Product characteristics Summary of Product characteristics Spanish 08-05-2012
Public Assessment Report Public Assessment Report Spanish 08-05-2012
Patient Information leaflet Patient Information leaflet Czech 08-05-2012
Summary of Product characteristics Summary of Product characteristics Czech 08-05-2012
Public Assessment Report Public Assessment Report Czech 08-05-2012
Patient Information leaflet Patient Information leaflet Danish 08-05-2012
Summary of Product characteristics Summary of Product characteristics Danish 08-05-2012
Public Assessment Report Public Assessment Report Danish 08-05-2012
Patient Information leaflet Patient Information leaflet German 08-05-2012
Summary of Product characteristics Summary of Product characteristics German 08-05-2012
Public Assessment Report Public Assessment Report German 08-05-2012
Patient Information leaflet Patient Information leaflet Estonian 08-05-2012
Summary of Product characteristics Summary of Product characteristics Estonian 08-05-2012
Public Assessment Report Public Assessment Report Estonian 08-05-2012
Patient Information leaflet Patient Information leaflet Greek 08-05-2012
Summary of Product characteristics Summary of Product characteristics Greek 08-05-2012
Public Assessment Report Public Assessment Report Greek 08-05-2012
Patient Information leaflet Patient Information leaflet English 08-05-2012
Summary of Product characteristics Summary of Product characteristics English 08-05-2012
Public Assessment Report Public Assessment Report English 08-05-2012
Patient Information leaflet Patient Information leaflet French 08-05-2012
Summary of Product characteristics Summary of Product characteristics French 08-05-2012
Public Assessment Report Public Assessment Report French 08-05-2012
Patient Information leaflet Patient Information leaflet Italian 08-05-2012
Summary of Product characteristics Summary of Product characteristics Italian 08-05-2012
Public Assessment Report Public Assessment Report Italian 08-05-2012
Patient Information leaflet Patient Information leaflet Latvian 08-05-2012
Summary of Product characteristics Summary of Product characteristics Latvian 08-05-2012
Public Assessment Report Public Assessment Report Latvian 08-05-2012
Patient Information leaflet Patient Information leaflet Lithuanian 08-05-2012
Summary of Product characteristics Summary of Product characteristics Lithuanian 08-05-2012
Public Assessment Report Public Assessment Report Lithuanian 08-05-2012
Patient Information leaflet Patient Information leaflet Hungarian 08-05-2012
Summary of Product characteristics Summary of Product characteristics Hungarian 08-05-2012
Public Assessment Report Public Assessment Report Hungarian 08-05-2012
Patient Information leaflet Patient Information leaflet Maltese 08-05-2012
Summary of Product characteristics Summary of Product characteristics Maltese 08-05-2012
Patient Information leaflet Patient Information leaflet Dutch 08-05-2012
Summary of Product characteristics Summary of Product characteristics Dutch 08-05-2012
Public Assessment Report Public Assessment Report Dutch 08-05-2012
Patient Information leaflet Patient Information leaflet Polish 08-05-2012
Summary of Product characteristics Summary of Product characteristics Polish 08-05-2012
Public Assessment Report Public Assessment Report Polish 08-05-2012
Patient Information leaflet Patient Information leaflet Portuguese 08-05-2012
Summary of Product characteristics Summary of Product characteristics Portuguese 08-05-2012
Public Assessment Report Public Assessment Report Portuguese 08-05-2012
Patient Information leaflet Patient Information leaflet Romanian 08-05-2012
Summary of Product characteristics Summary of Product characteristics Romanian 08-05-2012
Patient Information leaflet Patient Information leaflet Slovak 08-05-2012
Summary of Product characteristics Summary of Product characteristics Slovak 08-05-2012
Public Assessment Report Public Assessment Report Slovak 08-05-2012
Patient Information leaflet Patient Information leaflet Slovenian 08-05-2012
Summary of Product characteristics Summary of Product characteristics Slovenian 08-05-2012
Public Assessment Report Public Assessment Report Slovenian 08-05-2012
Patient Information leaflet Patient Information leaflet Finnish 08-05-2012
Summary of Product characteristics Summary of Product characteristics Finnish 08-05-2012
Public Assessment Report Public Assessment Report Finnish 08-05-2012
Patient Information leaflet Patient Information leaflet Swedish 08-05-2012
Summary of Product characteristics Summary of Product characteristics Swedish 08-05-2012
Public Assessment Report Public Assessment Report Swedish 08-05-2012
Patient Information leaflet Patient Information leaflet Norwegian 08-05-2012
Summary of Product characteristics Summary of Product characteristics Norwegian 08-05-2012
Patient Information leaflet Patient Information leaflet Icelandic 08-05-2012
Summary of Product characteristics Summary of Product characteristics Icelandic 08-05-2012

Search alerts related to this product

Alerts Zubrin тепоккалин tepoxalin

Zubrin тепоккалин tepoxalin

View documents history

Documents history Documents history

Zubrin